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Abstract: Musculoskeletal injuries are on the rise. First-line management of such injuries 
usually employs the RICE (rest, ice, compression, and elevation) approach to limit excessive 
inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) are also commonly used to limit 
inflammation and to control pain. Traumeel®, a preparation with bioregulatory effects is also 
used to treat the symptoms associated with acute musculoskeletal injuries, including pain and 
swelling. Traumeel is a fixed combination of biological and mineral extracts, which aims to 
apply stimuli to multiple targets to restore normal functioning of regulatory mechanisms. This 
paper presents the accumulating evidence of Traumeel’s action on the inflammatory process, 
and of its efficacy and tolerability in randomized trials, as well as observational and surveillance 
studies for the treatment of musculoskeletal injuries. Traumeel has shown comparable effective-
ness to NSAIDs in terms of reducing symptoms of inflammation, accelerating recovery, and 
improving mobility, with a favorable safety profile. While continued research and development 
is ongoing to broaden the clinical evidence of Traumeel in acute musculoskeletal injury and to 
further establish its benefits, current information suggests that Traumeel may be considered as 
an anti-inflammatory agent that is at least as effective and appears to be better tolerated than 
NSAIDs.
Keywords: Traumeel, inflammation, acute musculoskeletal injuries, nonsteroidal anti- 
inflammatory drugs
Introduction
Inactivity is recognized as an important predictor of mortality and morbidity, and the 
benefits of regular physical activity are well documented.1 A moderate amount of 
physical activity on most days can have substantial health benefits.2 However, partici-
pation in sports and other physical activities increases the risk of injury. The most 
common injuries are at the ankle, which, with an incidence of 1 per 100,000 people a 
day, account for about 20% of all sports injuries and usually comprise moderate liga-
ment sprains.1 Moreover, there are additional risks of musculoskeletal injury from 
innate factors, such as in people who are overweight,3 through excessive load, or who 
are elderly and prone to falls.4
Generally, the principle of the management of acute musculoskeletal injuries is to 
provide symptomatic relief so that a return to activity and rehabilitation can begin,5 
and the pre-injury level of function is regained without overtly compromising tissue 
healing.6,7 In this respect, nonsteroidal anti-inflammatory drugs (NSAIDs) are com-
monly used to limit inflammation and to control pain, and appear to facilitate the return 
to function.7 However, these drugs are not always well tolerated and alternatives may International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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need consideration.7 Such concerns are likely to contribute 
to the increase in complementary and alternative medical 
(CAM) practices.8
A frequently used preparation for the symptoms associ-
ated with acute musculoskeletal injuries, including inflam-
mation and pain, is Traumeel® (Biologische Heilmittel Heel 
GmbH, Baden-Baden, Germany), a fixed combination of 
biological and mineral extracts.9 The aim of this paper is to 
describe the conventional management of acute musculoskel-
etal injuries, focusing on NSAIDs and their use and limitations, 
and to consider Traumeel as an emerging option to NSAIDs 
for individuals who, for whatever reason, either cannot or 
prefer not to take NSAIDs.
Acute musculoskeletal injuries
Acute musculoskeletal injuries, such as sprains, strains, 
tendinopathy, and stress fractures, are a range of disorders 
involving ligaments, muscles, tendons, bones, and associated 
neurovasculature. Common causes include sudden impact, 
physical muscular overloads, or repetitive use of a joint or 
particular muscle group. Such injuries are associated with 
significant short-term disability and constitute a significant 
demand on primary and hospital care.
Conventional management of acute 
musculoskeletal injuries
Tissue processes following acute musculoskeletal injuries 
involve an acute inflammatory response at the injury site. 
Conventional management aims to control the pain, minimize 
secondary tissue injury, and restore the range of motion and 
voluntary muscle control.10 Decisions about the care of acute 
problems are made mostly on patients’ symptoms,11 and visits 
to a general practitioner are generally influenced by the 
perceived seriousness and duration of the injury.12 The avail-
ability of over-the-counter (OTC) medications makes it 
possible for consumers to treat many ailments without con-
sulting a healthcare professional,13 and OTC pain medication 
(eg, salicylates and paracetamol-based products) are fre-
quently used to cope with minor aches, pains, and injuries.
Although inflammation is a homeostatic mechanism 
and part of the body’s response to injury, excessive inflam-
mation can slow the healing process and cause tissue damage. 
  Excessive inflammation of acute musculoskeletal injuries 
can be limited by following the RICE (rest, ice, compression, 
and elevation) approach. The objective of RICE is to stop 
the injury-induced bleeding into the muscle tissue, thereby 
minimizing the injury extent.14 Additional medication is often 
required to achieve effective symptomatic relief. Treatments 
including hyaluronidase, low-dose heparin, aprotinin, and 
corticosteroids have been used in the management of various 
injuries, although there is little evidence of long-term effective-
ness or to support their use.15,16 Moreover, these approaches 
are associated with risks of adverse effects.15,17,18 Newer 
agents, such as Actovegin (calf-derived deproteinized hemo-
dialysate), injection of autologous red cells in and around a 
symptomatic tendon, sclerosant injections, topical glyceryl 
trinitrate, and polysulphated glycosaminoglycans may also 
be useful in tendon disorders, but their efficacy needs to be 
substantiated in larger controlled trials.17,18
NSAIDs have become synonymous with the manage-
ment of acute musculoskeletal injuries.7 They are some of 
the most widely used medications, and are reliable and 
effective when used appropriately for pain relief and to 
reduce inflammation. NSAIDs reduce pain through their 
influence on the peripheral nervous system, achieved through 
incomplete inhibition of the enzymes, cyclooxygenase-1 
(Cox-1) and cyclooxygenase-2 (Cox-2), which inhibit pros-
taglandin biosynthesis. Cox-2 is involved in inflammatory 
processes mediated by prostaglandins.
Side effects associated with NSAIDs are common 
(Table 1) and are generally a result of the inhibition of the 
“housekeeping” functions of prostaglandins by Cox-1, which 
is present in a variety of cell types. Most frequent are the 
effects on the gastrointestinal tract, the most common being 
gastritis and upper gastrointestinal ulcer and bleeding.19–22 
There may be effects on prostaglandin-mediated renal23–25 
and platelet function, an increased risk of myocardial 
  infarctions, hypertension and heart failure, as well as liver 
damage, blood dyscrasias, rashes, and hearing and vision 
impairment.23,26–29
A report of two US surveys of over 9602 respondents 
concluded that OTC NSAID analgesics were widely used, 
frequently taken inappropriately and potentially dangerous, 
and users were generally unaware of the risk of adverse 
events.30 A retrospective study of US medical records of 
about 12,000 patients on naproxen and 38,500 patients on 
ibuprofen found that the “real-world” risk of these patients 
sustaining a serious gastrointestinal event was 1.38- and 
1.54-times greater, respectively, than for those not taking 
such medications.31
Complications secondary to NSAID use are increasingly 
recognized in patients who are elderly; or with a previous his-
tory of gastrointestinal complications;23,26,32 pre-existing renal 
dysfunction, diabetes or heart failure; or with   cardiovascular International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Typical adverse events of nonsteroidal anti-inflammatory 
drugs
System/organ Adverse event
Cardiovascular system Thrombotic vascular incidents, including 
myocardial infarction
Gastrointestinal tract Nausea, vomiting, dyspepsia, gastritis, 
bleeding, ulceration
Hematopoiesis Thrombocytopenia, hypoprothrombinemia, 
anemia, granulocytopenia
Hypersensitivity  
reactions
Rashes, erythema, drug-induced eruptions, 
urticaria, angioedema, broncospasm, 
aspirin-induced asthma, Stevens–Johnson 
syndrome (very rarely)
Kidneys Renal failure, hematuria, proteinuria, 
sodium and water imbalance (fluid 
retention), interstitial nephritis, nephrotic 
syndrome, papillary necrosis
Liver Hepatic damage, abnormalities on 
liver function tests (eg, increased 
aminotransferase activity)
Nervous system Headache, dizziness, nervousness, 
depression, drowsiness, insomnia
Sense organs Hearing disturbances, vertigo, 
photosensitivity, eye changes
risk factors, such as obesity, dyslipidemia, and hypertension.29 
Moreover, there is the risk of drug interactions,33,34   particularly 
in the elderly who are likely to have other medical conditions 
and therefore taking multiple medications.
Although effective at reducing pain and inflammation, 
NSAIDs may not be appropriate particularly for those fre-
quently participating in sports. Masking pain may enable an 
individual to continue their sport or daily activities in the 
short term, but may lead to a worsening of the injury without 
realization of the damage being inflicted. Moreover, animal 
studies have demonstrated that anti-inflammatory treatment 
may not promote healing;7,35 NSAIDs have been shown to 
impair the return of mechanical strength following acute 
injury to bone, ligament, and tendon.7 Prostaglandin synthesis 
is required for factors regulating muscle regeneration, and 
Cox inhibition can affect expression of such factors.36
Patient choice
Patient preferences have been shown to have a direct impact 
on the outcome of therapy through psychological factors, 
such as belief in the medication and media coverage, or indi-
rectly via patient rates of adherence to treatment.37 Preference 
for a medication is based on several factors, including speed 
and degree of pain relief, symptom recurrence, functional 
disability, consistency of effect, ease of administration, and 
adverse events.38 A study to investigate patient   preferences 
for osteoarthritis treatment found the attributes significantly 
influencing treatment preference were the degree of joint 
aches, the level of physical mobility, and the risk of experi-
encing serious treatment-related adverse events.39 Thus, while 
some patients may find their treatment ineffective or prefer 
to avoid the risk of adverse effects,39 it is reasonable to assume 
that others may prefer an alternative treatment option. 
It therefore seems prudent to consider patients’ preferences29 
to encourage adherence.
Self-care is becoming increasingly popular,13 and govern-
ment policies are developing to support and empower people 
to treat themselves appropriately.40 Additionally, people want 
the opportunity for shared decision-making.41 In addition to 
standard conventional medical care, use of CAM therapies for 
routine healthcare is becoming increasingly popular.41 CAM 
therapies include dietary supplements, herbal medicine, 
  acupuncture, and biofeedback. Data suggest that many people 
have a holistic view of health, and believe that a combination 
of CAM and conventional medicine is superior to either 
approach alone.41 Notably, some prefer to avoid prescription 
medicines whenever possible, using them as a last resort. 
In the UK, patients have demonstrated such preference by 
purchasing alternative therapies privately, despite the provision 
of conventional medicines by their healthcare providers.42
Traumeel – an option in acute 
musculoskeletal injury management
what is Traumeel?
Traumeel is a fixed combination of diluted plant and mineral 
extracts (Table 2). It has been available over the counter in 
Germany for over 60 years and in Austria for over 40 years, 
and is currently available in approximately 50 countries, 
including the USA. The combination is currently used to treat 
acute musculoskeletal injuries, such as sprains and   traumatic 
injuries, and as supportive therapy in pain and inflammation 
of the musculoskeletal system. It can be used in the form of 
tablets, drops, injection solution, ointment, and gel.
The ingredients of Traumeel have been used for many years 
for therapeutic purposes, such as for pain (Atropa belladonna), 
inflammation (Echinacea), bruising (Arnica montana), wound 
healing (Matricaria recutita, Calendula officinalis), bleeding 
(Achillea millefolium), edema (Mercurius solubilis), and infec-
tions (Hepar sulfuris). Based on such observations, Traumeel 
was developed by the German physician, Dr Hans-Heinrich 
Reckeweg in the 1930s; he combined botanical and mineral 
substances to produce this natural medicine to treat musculo-
skeletal injuries and inflammation.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Components of Traumeel (eg, ointment, tablets, and ampoules)
Source of extract Characteristicsa Ointment 
(per 100 g)
Tablets 
(per 300 mg)
Ampoules for injection 
(per 2.2 mL)
Achillea millefolium  
(milfoil)
Hemorrhages, especially precapillary  
arteriovenous (anastomosis), oozing  
hemorrhages
90 mg 0.015 mg 0.0022 µL
Aconitum napellus  
(monkshood)
Fever with hot, dry skin, neuralgia,  
inflammatory rheumatism; improvement  
of the vasotonia; analgesic, hemostatic
5 mg 0.03 mg 0.0132 µL
Arnica montana  
(mountain arnica)
To stimulate the healing of wounds,  
fractures, dislocations, contusions,  
hemotomas, myocardial weakness,  
neuralgia, myalgia, analgesic, hemostatic
1.5 mg 0.15 mg 0.022 µL
Atropa belladonna  
(deadly nightshade)
Localized reaction phases, cerebral  
sensitivity with cramp and delirium
5 mg 0.0075 mg 0.022 µL
Bellis perennis  
(daisy)
Dislocations, contusions, sensation  
of soreness in the abdominal wall/cavity,  
exudative processes, resorption of edema
100 mg 0.06 mg 0.011 µL
Calendula officinalis  
(calendula)
Slowly healing wounds, promotes  
granulation, analgesic
450 mg 0.15 mg 0.022 µL
Matricaria recutita  
(chamomile)
Anti-inflammatory; stimulates granulation,  
promotes healing in difficult healing  
wounds and ulcers; fistulae, hemorrhoids,  
mastitis, intertrigo, aphthous stomatitis,  
conditions of restlessness and excitation,  
disorders of dentition, otitis media,  
glandular swellings
150 mg 0.024 mg 0.0022 µL
Echinacea angustifolia  
(narrow-leaved  
cone flower)
Increase in the mesenchymal defences;  
inflammation of all kinds and locations;  
septic processes; hyaluronidase inhibiting,  
anti-inflammatory action
150 mg 0.06 mg 0.0055 µL
Echinacea purpurea  
(purple cone flower)
Increase in the mesenchymal defences;  
inflammation of all kinds and locations;  
septic processes; hyaluronidase inhibiting,  
anti-inflammatory action
150 mg 0.06 mg 0.0055 µL
Hamamelis virginiana  
(witch hazel)
venous stasis, varicose veins, (thrombo-)  
phlebitis, crural ulcers, hemorrhoids,  
venous hemorrhages, anti-inflammatory,  
analgesic
450 mg 0.15 mg 0.022 µL
Calcium sulphide  
(otherwise:  
Hepar sulfuris)
Tendency to suppuration, especially  
on the skin and lymph glands (furuncles,  
pyodermia, panaris, phlemons), tonsillar  
abscesses, chalazions, hordeolums,  
hemicrania, urinary disorders,  
hypersensitivity to cold and draughts
0.000025 mg 0.0000003 mg 0.0000022 µL
Hypericum perforatum  
(St John’s wort)
Neural and cerebral injuries,  
eg, commotio cerebri neural pains  
upon or after injuries hemostatic
0.00009 mg 0.03 mg 0.0066 µL
Mercurico-amidonitrate  
(otherwise: Mercurius  
solubilis Hahnemanni)
Suppurations, abscesses, gingivitis,  
stomatitis, nasopharngeal catarrh,  
catarrh of the sinuses, cholangitis,  
shrinking action on edematous conditions
0.00004 mg 0.0000003 mg 0.0000011 µL
Symphytum officinale  
(comfrey)
To accelerate callus formation in fractures  
periostitis, causalgia, disorders arising  
from amputation stumps contusions
0.01 mg 0.00000024 mg 0.0000022 µL
excipients – Cetostearyl alcohol,  
paraffin, 13.8% alcohol
6 mg lactose,  
1.5 mg Mg-stearate
0.9% saline  
solution
Copyright © Biologische Heilmittel Heel GmbH.
Notes: In some countries the number of ingredients and their concentration may vary slightly.  aCharacteristics with reference to: Reckeweg H-H. Materia Medica – 
homoeopathia antihomotoxica. 4th edition. Baden-Baden. Germany: Aurelia verlag 2007.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Mechanism of anti-inflammatory action
The anti-inflammatory effect of Traumeel results from the 
activity of the various components on the different phases 
of the inflammatory response. For example, Aconitum napel-
lus, Matricaria recutita, Hamamelis virginiana, and Hyperi-
cum may reduce pain associated with inflammation; 
Mercurius solubilis may be anti-inflammatory; while Arnica 
montana, Calendula officinalis, Echinacea, and Symphytum 
may accelerate wound healing.43 Study of single components 
of Traumeel has shown that Arnica montana, Hamamelis 
virginiana, Achillea millefolium, Aconitum napellus, Atropa 
belladonna, and Mercurius solubilus exert a considerable 
inhibitory effect on edema, while other components have a 
pro-inflammatory effect (Calendula officinalis, Echinacea 
purpurea, Matricaria recutita); yet others are reported not 
to influence the development of edema (Symphytum, Hyperi-
cum, Hepar sulfuris).43 However, the effect of Traumeel was 
found to be greater than the ‘sum’ of the active components, 
suggesting a synergistic interaction between all components 
of the preparation have a bearing on the final effect.43
Despite its long history of use as an anti-inflammatory 
agent, little was known until relatively recently regarding 
Traumeel’s effects on immune cell function. Preclinical 
evidence is provided by an in vitro study investigating 
the effects of Traumeel on human T-cells, monocytes, and 
gut epithelial cells in terms of their ability to secrete pro-
inflammatory mediators interleukin-1beta (IL-1β), tumor 
necrosis factor alpha (TNFα), and interleukin-8 (IL-8).44 
Traumeel was found to modulate the secretion of these 
mediators, inhibiting secretion in resting and activated cells 
by up to 54%–70% (p , 0.01 for all cells). These findings 
suggest that Traumeel acts on cells of the ‘mobile’ arm of 
the immune system (blood-borne leukocytes) and also on the 
first line of defense of the ‘nonmobile’ gut-associated 
immune system (gut epithelial cells).
Other preclinical evidence suggest that Traumeel reduces 
microvascular leakiness to albumin in the mesenteric micro-
circulation and subsequent mast cell degranulation in rats 
exposed to daily 15-min episodes of 90-dB SPL noise for 
3–5 weeks.45 Compared to controls, the number and area of 
leaks per venule in the rats that received Traumeel were 
significantly smaller and mast cell degranulation was signifi-
cantly lower than those in rats exposed to noise only. This result 
is consistent with the in vitro study showing that Traumeel 
inhibited secretion of pro-inflammatory mediators from 
immune cells such as monocytes and T cells,44 and it is sug-
gested that Traumeel may act by stabilizing immune cells.
There is evidence to suggest that Traumeel does not act 
in the same way as NSAIDs.46 While reducing acute local 
inflammation (first phase of adjunct arthritis) in vivo, the 
preparation did not affect granulocyte function (eg, super-
oxide anion production and adhesion) or human platelet 
adhesion in vitro, indicating that the normal defensive and 
homeostatic functions of these cells are preserved. Traumeel 
appears to act by regulating the orchestration of the overall 
process of acute local inflammation rather than by interacting 
with a specific cell type or biochemical mechanism. Further 
studies concluded that Traumeel also seems to act by speed-
ing up the healing process instead of blocking edema devel-
opment from the start.43
Additionally, Traumeel may play a role in situations 
where regulatory lymphocytes actively help control inflam-
matory reactions by producing the messenger, transforming 
growth factor beta (TGF-β).47 Low potencies of plant extracts 
(including Bellis perennis and Atropa belladonna) used 
in Traumeel have demonstrated stimulatory effects on 
  lymphocyte synthesis of the inhibitory cytokine TGF-β in 
whole blood cultures. Through TGF-β synthesis, other pro-
  inflammatory T-lymphocytes (via, for example, TNFα 
and IL-1) are prevented from supporting the inflammatory 
process. This action has been supported by results in vivo.48
The nuclear factor-κB (NF-κB) family of transcription 
factors has a crucial role in the expression of genes that control 
the inflammatory response.49 In acute inflammation, NF-κB is 
activated rapidly in response to a wide range of stimuli (includ-
ing pro-inflammatory cytokines, particularly TNF and IL-1) 
and increases the expression of several pro-inflammatory 
cytokines and chemokines. Traumeel, therefore, indirectly 
inhibits the activation of NF-κB by its effects on pro-inflammatory 
cytokines. There is evidence that it may also directly inhibit 
helenalin, an anti-inflammatory sesquiterpene lactone found 
in the asteracea plant family (which includes Arnica montana 
and Bellis perennis, components of Traumeel) and has been 
shown to selectively inhibit NF-κB.50
The concept of ‘U’- or ‘J’-shaped dose-response curves 
(the dose-response hypothesis of which is also referred to as 
hormesis) is well established.51 The pharmacokinetic 
response of Traumeel, which comprises low concentrations 
of each component, is biphasic – high dilutions have no 
effect, but an effect is seen within a certain range of low 
concentrations, after which higher doses have the opposite 
effect. Between dilutions of 10-1 to 10-7, Traumeel has a 
selective inhibitory effect on the pro-inflammatory mediators, 
IL-1β, TNFα, and IL-8.44International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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evidence of effect – randomized 
controlled clinical trials (RCT)
There are several studies reported in the literature on the use 
of Traumeel for traumatic injuries (Table 3). A PubMed 
search was carried out to identify trials on Traumeel use 
in adults (full publications, in English or with English 
  translation), associated with sports injuries, musculoskeletal 
traumatic injuries, and injuries accompanied by inflammation. 
Studies in pediatrics, inflammatory disorders, such as stoma-
titis and asthma, and use in surgery and dentistry, were 
excluded. The manufacturer was also contacted to ensure all 
relevant fully published studies were included. The studies 
of Traumeel use in adults identified with traumatic injuries 
are reviewed below.
In general, the studies required treatment to be within a 
few days of injury. They excluded patients already undergo-
ing treatment for the injury (including medications), and 
patients with multiple injuries, previous injury of the same 
joint, degenerative joints, fractures, and open wounds. 
Additionally, treatment groups in terms of patient population 
and injury characteristics were generally comparable at 
baseline.
High quality research on therapies other than those 
  considered to be conventional is considered to be lacking.52 
The effectiveness and tolerability of Traumeel for acute 
musculoskeletal injuries has been evaluated in four RCTs. 
The first was a placebo-controlled, double-blind study in 
73 patients (69 evaluated) with ankle sprains incurred during 
sports activities.53 Patients were treated with Traumeel 
  ointment (n = 33) or placebo (n = 36) seven times within a 
2-week period. Compression bandages were applied over 
the ointment, and electrotherapy was also administered as 
basic therapy. Ankle mobility (joint angulation), which 
would occur naturally over time, had improved after 10 days 
of treatment in both treatment groups, but improvement 
was faster and more frequent with Traumeel than with 
placebo (Fischer’s Exact Test; p = 0.03). Additionally, 
significantly more patients in the Traumeel group reported 
no pain with movement on Day 10 (28 versus 13 patients; 
Fischer’s Exact Test p # 0.0001, p # 0.0003 with Bonfer-
roni adjusted).
Traumeel ointment has also been evaluated in a placebo-
controlled, double-blind study in 68 outpatients with a range 
of musculoskeletal sports injuries.54 An occlusive dressing 
and cold compresses were applied for half an hour after 
application. After 15 days of twice-daily treatment, the reduc-
tion in swelling (p = 0.0214), as measured by joint circum-
ference, and pain (p = 0.0005), assessed by a pain index score, 
was significantly greater in patients using Traumeel than in 
those receiving placebo. These findings were clinically highly 
significant. There was no statistical   difference in skin tem-
perature between the two groups. Both patients and physi-
cians rated the overall effectiveness of Traumeel superior to 
placebo (p # 0.001).
Use of Traumeel injection solution for the treatment of 
traumatic hemarthrosis of the knee was studied in a placebo-
controlled double-blind trial in 73 outpatients.55 Three 2 mL 
intra-articular injections (and, where necessary, subsequent 
puncture of the joint to enable escape of fluid) were given 
over a period of 8 days. A support dressing was applied, and 
cold compresses were permitted. After a single injection, 
13.5% of patients treated with Traumeel required further 
punctures compared with 25% of the placebo group. The 
punctuate was still bloody on Day 8 for 5.4% and 19.4% 
of patients in the Traumeel and placebo groups, respectively. 
Therapeutic success – improvement in the degree of joint 
movement between the healthy knee and injured (treated) 
knee of 0 to 10 degrees, plus an improvement in the differ-
ence in circumference of the joints of 0.5 cm maximum – was 
reported for 64.9% of the Traumeel group and 36.1% of 
the placebo group on Day 8; with mean differences in mobility 
reducing from 48.4° to 8.3° and from 41.4° to 18.2°, respec-
tively, and with mean differences in joint circumference 
reducing from 2.02 to 0.54 and from 2.18 to 1.06 cm, respec-
tively, on Day 8. Reductions in pain over time were greater 
in the Traumeel group than in the group receiving placebo, 
with 89.2% and 63.9% of patients reporting no pain after 
8 days, respectively.
Nonrandomized observational studies 
and surveillance studies
While the randomized clinical trial is considered the “gold 
standard” for evaluating clinical therapies, patients enrolled 
into such trials (which exclude patients not meeting certain 
predefined criteria) may not be representative of the broad 
range of individuals treated in clinical practice.56 As such, 
the addition of observational, nonrandomized studies is 
considered to be complementary to these trials,57   particularly 
with regards to tolerability data. Their limitations (possible 
selection and evaluation bias) and advantages (more closely 
related to clinical practice) are well recognized; however, 
it is also reasonable to assume that physicians would 
like to see the best results for their patients regardless of 
treatment.
Traumeel has been compared with conventional therapy 
in multicenter, observational, nonrandomized studies where International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Clinical trials on Traumeel in acute musculoskeletal injury
Study design Indication Number  
of patientsa
Therapies Main outcomes
Randomized, double-blind trials
Zell et al,53  
Single center study  
in Germany  
2-weeks duration
Ankle sprains N = 73  
n = 69
Traumeel ointment  
vs placebo ointment
More rapid and more frequent improvement  
in upper-ankle mobility in the Traumeel  
group vs placebo at 2 weeks.
Böhmer and Ambrus,54  
Single center study  
in Germany  
15-days duration
varied  
musculoskeletal  
sport injuries
N = 68  
n = 68
Traumeel ointment  
vs placebo ointment
Reduction in swelling and pain significantly  
greater in patients using Traumeel vs placebo  
after 15 days. No difference between  
the groups in skin temperature. Overall  
effectiveness of Traumeel was superior  
to placebo.  
Traumeel was well tolerated with  
all patients rating the treatment as  
“good” or “very good”.
Thiel and Borho,55  
Single center study  
in Germany  
8-days duration
Post traumatic  
hemarthrosis  
of the knee
N = 80  
n = 73
Traumeel injections  
vs physiological saline  
injections
Greater degree of movement and greater  
reductions in pain and swelling with Traumeel   
vs saline after 3 injections over 8 days.  
No treatment-related adverse events.
Observational studies
Birnesser et al,58  
Multicenter study  
in Germany;  
nonrandomized  
2-week duration
epicondylitis N = 184  
n = 163
Traumeel injections  
vs unspecified NSAID  
(mainly diclofenac)
Noninferior effects of Traumeel on three  
pain relief and two joint mobility variables.  
Global outcome rated as “good” and  
“very good” by 71% of Traumeel patients  
and 44% of NSAID patients.  
Tolerability assessed as “very good” by 88% of 
Traumeel patients and 45% NSAIDs patients.
Schneider et al,9  
Multicenter study  
in Germany;  
nonrandomized  
28-days duration
Tendinopathy  
of varying etiology  
(based on excessive  
tendon load rather  
than inflammation)
N = 457  
n = 357
Traumeel ointment  
vs diclofenac 1% gel
Traumeel noninferior to diclofenac on all pain   
and mobility variables after 28 days. In the  
Traumeel and diclofenac groups, respectively,   
the mean (±standard deviation) reduction  
in summary score for pain-related variables  
was 5.3 ± 2.7 and 5.0 ± 2.7 units, and for  
mobility-related variables was 4.2 ± 3.8 and  
3.7 ± 3.4 units. Global evaluation of therapies  
rated as “very good” or “good” by 88%  
of Traumeel cases and 82% of diclofenac cases.
Schneider et al,62  
Multicenter study  
in Germany;  
prospective;  
nonrandomized  
Up to 3 months  
duration
various  
musculoskeletal  
injuries
N = 133
n = 132
Traumeel (tablets  
and gel) vs conventional  
management
Rates of complete symptomatic resolution  
at the end of therapy were similar between  
treatment groups, occurring in 59.4%  
of Traumeel-treated patients and 57.8%  
of the conventionally treated group.  
No adverse events reported in the Traumeel  
group vs six (6.3%) mild-moderate events  
in the conventional group. Physician-rated  
tolerability was “very good” for 90%  
of Traumeel cases vs 50% of conventional  
cases (p = 001).
Surveillance studies
Zenner and weiser,61  
Multicenter study  
in Germany, Italy,  
and Portugal; prospective;  
randomized; standardized  
questionnaires
variety of injuries  
(eg, sprains, post- 
traumatic edema),  
and degenerative  
and inflammatory  
conditions (arthrosis,  
and epicondylitis)
N = 1359 Traumeel tablet or  
drop forms (69% tablets,  
29% drops, 2% both).  
One-third of patients  
were treated without  
other therapies (drug  
and nondrug)
Symptom improvement occurred in about  
half of all patients within the first week  
of treatment and an additional 34%  
of patients within 1 to 3 weeks. Treatment  
rated as “very good” or “good” by 83%  
of cases.
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treatment groups were comparable at baseline (Table 3). 
Traumeel has demonstrated noninferiority to NSAIDs 
(unspecified; 52%, diclofenac) in patients with diagnosed 
epicondylitis58 and to diclofenac, specifically, in patients with 
tendinopathy9 on all pain relief (eg, pain at rest, local pressure 
pain, pain with movements, and at muscle load and contrac-
tion) and joint mobility (eg, extensional and torsional joint 
mobility) variables.
Multicenter drug surveillance studies have indicated that 
Traumeel is frequently used for a variety of injuries, including 
bruises, sprains, hematomas, and post-traumatic edema, as well 
as degenerative and inflammatory conditions, such as arthrosis, 
frozen shoulder, carpal tunnel syndrome, and epicondylitis.59–61 
Assessed in 3241 cases, Traumeel injection solution was used 
most frequently in arthrosis (19%),   particularly in inflammation 
of the knee and degenerative joint diseases, and also for 
myogelosis (12%), sprains (12%), periarthropathia humer-
oscapularis (10%), epicodylitis (10%), and tendinovaginitis 
(8%).59 Traumeel injection was used as monotherapy by 19% 
of patients; the percentage of these patients was highest for 
sprains (27%). Of 3422 patients using Traumeel ointment, this 
was most frequently applied for sprains (21%), followed by 
hematomas (8%), myogelosis (8%),   contusion (8%), 
tenosynovitis (8%), and arthrosis (9%).60 Traumeel ointment 
was used as monotherapy by 38% of patients; it was applied as 
monotherapy in about half or more of patients with hematomas, 
contusions, and sprains. The effectiveness and tolerability of 
Traumeel is generally reported to be “very good” or “good”.
Tolerability
Traumeel is reported to be well tolerated and without 
  treatment-related adverse effects.9,54,55,58–62 There are no 
reports of disease exacerbation or drug interactions, making 
Traumeel an interesting option for people (particularly the 
elderly) who have other medical condition(s) and are taking 
other medication(s).
Out of the treatment populations of the two aforementioned 
multicenter drug monitoring trials (n = 6913), there were only 
32 (0.5%) reports of adverse reactions when using Traumeel.59,60 
These mainly involved mild, transient, local skin reactions 
(redness, pruritus, heat; interpreted as allergic reactions), which 
could not clearly be assigned to Traumeel as other therapies 
were also used. Tolerability was rated as “very good” in twice 
as many patients using Traumeel compared with conventionally-
treated patients when assessed by patients58 and physicians.62
The clinical safety of Traumeel tablets taken daily for 
4 weeks was evaluated in 20 healthy individuals in a four-week 
study.63 There were no significant differences in vital signs or 
laboratory data (hematology, blood biochemistry, occult blood 
in stool) at baseline and at study term. Adverse events were 
reported by about half of the subjects (n = 11) who reported a 
total of 36 events. Common ones included headache 
(15 events), diarrhoea/stomach discomfort/bloating (6 events), 
feelings of nausea, and perceptions of “feeling buzzed” 
(2 events). All adverse events were mild or moderate in severity, 
and resolved with continued use of Traumeel, and none was 
considered probably/definitely related to this therapy.
Table 3 (Continued)
Study design Indication Number  
of patientsa
Therapies Main outcomes
Zenner and  
Metelmann,59  
Multicenter, drug  
monitoring trial
variety of injuries,  
and degenerative  
and inflammatory  
conditions
N = 3241 Traumeel injection.  
Used exclusively by  
17% of patients; adjuvant 
medications taken by 47%  
of patients; 65% received  
nonmedication therapies
Used most frequently in arthrosis (19%),  
particularly in inflammation of the knee  
and degenerative joint diseases, myogelosis  
(12%), sprains (12%), periarthropathia  
humeroscapularis (10%), epicodylitis (10%),  
and tendinovaginitis (8%). Traumeel, used  
exclusively, was highest for sprains (27%).  
Outcomes of Traumeel therapy was assessed  
as “very good” or “good” by 79% of patients.
Zenner and  
Metelmann,60  
Multicenter, drug  
monitoring trial
variety of injuries,  
and degenerative  
and inflammatory  
conditions
N = 3422 Traumeel ointment.  
Used exclusively by 38%  
of patients; adjuvant  
medications taken by  
30% of patients; 52%  
received nonmedication 
therapies
Used most frequently for sprains (21%), 
hematomas (8%), myogelosis (8%), contusion  
(8%), tenosynovitis (8%), and arthrosis (9%).  
Traumeel was used exclusively by half or 
more of patients with hematomas, contusions   
and sprains. Outcomes of Traumeel therapy  
was assessed as “very good” or “good” by 
87% of patients.
Notes: aN = recruited patient population, n = efficacy population.
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Conclusion
There is a growing evidence-base supporting the effectiveness 
of Traumeel, alone and in combination with other medicines 
and/or nonmedicine therapies, in treating acute   musculoskeletal 
injuries. Traumeel appears to be well tolerated, with no signs 
of severe adverse events and no evidence of gastrointestinal 
bleeding.63 NSAIDs may cause gastrointestinal ulceration and 
bleeding, and are a particular risk for patients with diseases, 
on co-medications, or who are elderly. A recent consensus by 
international experts on “muscle strains” concluded against 
automatic prescription of a NSAID for all muscle strains, 
as they may predispose to recurrences by masking pain.64 
  However, they also agreed that controlling inflammation may 
be beneficial to minimize early damage and subsequent loss 
of function.64 Traumeel may thus provide an alternative anti-
inflammatory and analgesic agent for these patients.
There is also growing insight into the mechanisms of 
action of this therapy on immune cell function. However, 
research behind CAM therapies is indisputably lacking, with 
RCTs reported to comprise only about 10% of published 
original articles in sport and exercise medicine.65 The level 
of scientific evidence supporting use of Traumeel is consid-
ered still to be low due to the lack of clinical trials. However, 
there is no more justification than expert opinion for the use 
of the vast majority of other practices for musculoskeletal 
injuries, including ice and compression.64 Regardless, further 
double-blinded randomized trials are required to increase 
Traumeel’s general acceptance as an emerging option to 
NSAIDs and other conventional drugs.
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